Related references
Note: Only part of the references are listed.Lack of NKG2D in MAGT1-deficient patients is caused by hypoglycosylation
Eline Blommaert et al.
HUMAN GENETICS (2022)
Estimating the global burden of Epstein-Barr virus-related cancers
Yide Wong et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)
A Double-Blind, Placebo-Controlled, Crossover Study of Magnesium Supplementation in Patients with XMEN Disease
Samuel D. Chauvin et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2022)
Longitudinal Analysis Suggests Epstein--Barr as Cause of Multiple Sclerosis
[Anonymous]
CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)
Co-Stimulatory Molecules during Immune Control of Epstein Barr Virus Infection
Christian Muenz
BIOMOLECULES (2022)
KSHV/HHV8-mediated hematologic diseases
Ethel Cesarman et al.
BLOOD (2022)
Cancers associated with human gammaherpesviruses
Kwun Wah Wen et al.
FEBS JOURNAL (2022)
Therapeutic options for CTLA-4 insufficiency
David Egg et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)
XMEN saved by magnesium
Vaishnavi V. Iyengar et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2022)
Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis
Kjetil Bjornevik et al.
SCIENCE (2022)
Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells
Paul J. Collins et al.
BLOOD (2021)
Successful hematopoietic stem cell transplantation in a 4-1BB deficient patient with EBV-induced lymphoproliferation
Christine Wildermann et al.
CLINICAL IMMUNOLOGY (2021)
Immunity to EBV as revealed by immunedeficiencies
Benjamin Fournier et al.
CURRENT OPINION IN IMMUNOLOGY (2021)
PD-1 Blockade Aggravates Epstein-Barr Virus+ Post-Transplant Lymphoproliferative Disorder in Humanized Mice Resulting in Central Nervous System Involvement and CD4+ T Cell Dysregulations
Valery Volk et al.
FRONTIERS IN ONCOLOGY (2021)
Future directions in Hodgkin lymphoma: checkpoint inhibitors and beyond
Sanjal Desai et al.
LEUKEMIA & LYMPHOMA (2021)
Kaposi's sarcoma-associated herpesvirus T cell responses in HIV seronegative individuals from rural Uganda
Angela Nalwoga et al.
NATURE COMMUNICATIONS (2021)
Cytotoxic CD4+T-cells specific for EBV capsid antigen BORF1 are maintained in long-term latently infected healthy donors
Alexander Dowell et al.
PLOS PATHOGENS (2021)
CD27 is required for protective lytic EBV antigen-specific CD8+ T-cell expansion
Yun Deng et al.
BLOOD (2021)
Castleman disease
Antonino Carbone et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
Epstein Barr Virus Exploits Genetic Susceptibility to Increase Multiple Sclerosis Risk
Fabienne Laederach et al.
MICROORGANISMS (2021)
Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma
Corey Smith et al.
NPJ PRECISION ONCOLOGY (2021)
Primary immunodeficiencies reveal the molecular requirements for effective host defense against EBV infection
Stuart G. Tangye et al.
BLOOD (2020)
Defective glycosylation and multisystem abnormalities characterize the primary immunodeficiency XMEN disease
Juan C. Ravell et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Vaccination against the Epstein-Barr virus
Julia Ruhl et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2020)
Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis
Catherine de Martel et al.
LANCET GLOBAL HEALTH (2020)
An Update on XMEN Disease
Juan C. Ravell et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2020)
The Epstein-Barr Virus Major Tegument Protein BNRF1 Is a Common Target of Cytotoxic CD4+ T Cells
Dinesh Adhikary et al.
JOURNAL OF VIROLOGY (2020)
Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency
Sujal Ghosh et al.
BLOOD (2020)
EBV renders B cells susceptible to HIV-1 in humanized mice
Donal McHugh et al.
LIFE SCIENCE ALLIANCE (2020)
Rapid identification and characterization of infected cells in blood during chronic active Epstein-Barr virus infection
Benjamin Fournier et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial
Catherine S Diefenbach et al.
Lancet Haematology (2020)
Mechanism of EBV inducing anti-tumour immunity and its therapeutic use
Il-Kyu Choi et al.
NATURE (2020)
Immunodeficiency and EBV-induced lymphoproliferation caused by 4-1BB deficiency
Mohammed F. Alosaimi et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Regulatory T cells in cancer immunosuppression - implications for anticancer therapy
Yosuke Togashi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Kaposi sarcoma
Ethel Cesarman et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
Takahiro Kamada et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
CD8+ T cells retain protective functions despite sustained inhibitory receptor expression during Epstein-Barr virus infection in vivo
Bithi Chatterjee et al.
PLOS PATHOGENS (2019)
Primary EBV Infection Induces an Acute Wave of Activated Antigen-Specific Cytotoxic CD4+ T Cells
Benjamin J. Meckiff et al.
JOURNAL OF IMMUNOLOGY (2019)
A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis
Douglas B. Johnson et al.
NATURE MEDICINE (2019)
Epstein-Barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection
Paulina Mrozek-Gorska et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study
Thomas S. Uldrick et al.
JAMA ONCOLOGY (2019)
CD137 deficiency causes immune dysregulation with predisposition to lymphomagenesis
Ido Somekh et al.
BLOOD (2019)
Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases
Sylvain Latour et al.
IMMUNOLOGICAL REVIEWS (2019)
Recurrent inflammatory disease caused by a heterozygous mutation in CD48
Benjamin Volkmer et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Concomitant PIK3CD and TNFRSF9 deficiencies cause chronic active Epstein-Barr virus infection of T cells
Remy Rodriguez et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
Latency and lytic replication in Epstein-Barr virus-associated oncogenesis
Christian Muenz
NATURE REVIEWS MICROBIOLOGY (2019)
The Global Landscape of EBV-Associated Tumors
Claire Shannon-Lowe et al.
FRONTIERS IN ONCOLOGY (2019)
MicroRNAs of Epstein-Barr Virus Attenuate T-Cell-Mediated Immune Control In Vivo
Anita Murer et al.
MBIO (2019)
Immunodeficiencies that predispose to pathologies by human oncogenic γ-herpesviruses
Blossom Damania et al.
FEMS MICROBIOLOGY REVIEWS (2019)
Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!
Melanie L. Grant et al.
BLOOD REVIEWS (2018)
Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects
Charlotte Schwab et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
Primary Epstein-Barr virus infection
Samantha K. Dunmire et al.
JOURNAL OF CLINICAL VIROLOGY (2018)
Dysregulation of Epstein-Barr Virus Infection in Hypomorphic ZAP70 Mutation
Akihiro Hoshino et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
Response to Checkpoint Inhibitor Therapy in Advanced Classic Kaposi Sarcoma: A Case Report and Immunogenomic Study
James Saller et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4+ and CD8+ T cell responses
Il-Kyu Choi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Epstein–Barr Virus and Cancer
Paul J. Farrell
Annual Review of Pathology-Mechanisms of Disease (2018)
High frequencies of asymptomatic Epstein-Barr virus viremia in affected and unaffected individuals with CTLA4 mutations
Akihiro Hoshino et al.
CLINICAL IMMUNOLOGY (2018)
Increased Risk for Malignancies in 131 Affected CTLA4 Mutation Carriers
David Egg et al.
FRONTIERS IN IMMUNOLOGY (2018)
Large Deletion of MAGT1 Gene in a Patient with Classic Kaposi Sarcoma, CD4 Lymphopenia, and EBV Infection
Immacolata Brigida et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2017)
Kaposi sarcoma herpesvirus pathogenesis
Giuseppe Mariggio et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2017)
Chronic Active Epstein-Barr Virus Disease
Hiroshi Kimura et al.
FRONTIERS IN IMMUNOLOGY (2017)
Primary B Lymphocytes Infected with Kaposi's Sarcoma-Associated Herpesvirus Can Be Expanded In Vitro and Are Recognized by LANA-Specific CD4+ T Cells
Samantha M. Nicol et al.
JOURNAL OF VIROLOGY (2016)
PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model
Shi-Dong Ma et al.
PLOS PATHOGENS (2016)
Azidothymidine Sensitizes Primary Effusion Lymphoma Cells to Kaposi Sarcoma-Associated Herpesvirus-Specific CD4+T Cell Control and Inhibits vIRF3 Function
Samantha J. Williamson et al.
PLOS PATHOGENS (2016)
The immunology of Epstein-Barr Virus Induced Disease
Graham S. Taylor et al.
ANNUAL REVIEW OF IMMUNOLOGY VOL 33 (2015)
Role of the 2B4 Receptor in CD8+ T-Cell-Dependent Immune Control of Epstein-Barr Virus Infection in Mice With Reconstituted Human Immune System Components
Obinna Chijioke et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Kaposi Sarcoma-Associated Herpesvirus-Associated Malignancies: Epidemiology, Pathogenesis, and Advances in Treatment
Manisha Bhutani et al.
SEMINARS IN ONCOLOGY (2015)
LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis
Shi-Dong Ma et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Role for early-differentiated natural killer cells in infectious mononucleosis
Tarik Azzi et al.
BLOOD (2014)
XLP: Clinical Features and Molecular Etiology due to Mutations in SH2D1A Encoding SAP
Stuart G. Tangye
JOURNAL OF CLINICAL IMMUNOLOGY (2014)
Virus and Autoantigen-Specific CD4+T Cells Are Key Effectors in a SCID Mouse Model of EBV-Associated Post-Transplant Lymphoproliferative Disorders
Stefanie Linnerbauer et al.
PLOS PATHOGENS (2014)
Inherited human OX40 deficiency underlying classic Kaposi sarcoma of childhood
Minji Byun et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Mg2+ Regulates Cytotoxic Functions of NK and CD8 T Cells in Chronic EBV Infection Through NKG2D
Benjamin Chaigne-Delalande et al.
SCIENCE (2013)
Spontaneous Lytic Replication and Epitheliotropism Define an Epstein-Barr Virus Strain Found in Carcinomas
Ming-Han Tsai et al.
CELL REPORTS (2013)
Human Natural Killer Cells Prevent Infectious Mononucleosis Features by Targeting Lytic Epstein-Barr Virus Infection
Obinna Chijioke et al.
CELL REPORTS (2013)
T-cell immunity to Kaposi sarcoma-associated herpesvirus: recognition of primary effusion lymphoma by LANA-specific CD4+ T cells
Shereen Sabbah et al.
BLOOD (2012)
Expansion of somatically reverted memory CD8+ T cells in patients with X-linked lymphoproliferative disease caused by selective pressure from Epstein-Barr virus
Umaimainthan Palendira et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency)
Jana Pachlopnik Schmid et al.
BLOOD (2011)
Cytotoxic CD4+ T Cell Responses to EBV Contrast with CD8 Responses in Breadth of Lytic Cycle Antigen Choice and in Lytic Cycle Recognition
Heather M. Long et al.
JOURNAL OF IMMUNOLOGY (2011)
Molecular Pathogenesis of EBV Susceptibility in XLP as Revealed by Analysis of Female Carriers with Heterozygous Expression of SAP
Umaimainthan Palendira et al.
PLOS BIOLOGY (2011)
Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets
Andrew D. Hislop et al.
BLOOD (2010)
Monofunctional and Polyfunctional CD8+ T Cell Responses to Human Herpesvirus 8 Lytic and Latency Proteins
Lauren Lepone et al.
CLINICAL AND VACCINE IMMUNOLOGY (2010)
Whole-exome sequencing-based discovery of STIM1 deficiency in a child with fatal classic Kaposi sarcoma
Minji Byun et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Infectious Mononucleosis
Katherine Luzuriaga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Priming of protective T cell responses against virus-induced tumors in mice with human immune system components
Till Strowig et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
T Cell-Mediated Control of Epstein-Barr Virus Infection in Humanized Mice
Misako Yajima et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
The CD8 and CD4 T-Cell Response against Kaposi's Sarcoma-Associated Herpesvirus Is Skewed Towards Early and Late Lytic Antigens
Rebecca C. Robey et al.
PLOS ONE (2009)
Changes in T-Cell Responses Against Human Herpesvirus-8 Correlate with the Disease Course of Iatrogenic Kaposi's Sarcoma in a Patient with Undifferentiated Arthritis
Patrizia Barozzi et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2009)
Changes in the immune responses against human herpesvirus-8 in the disease course of posttransplant Kaposi sarcoma
Patrizia Barozzi et al.
TRANSPLANTATION (2008)
Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma
E. Anderton et al.
ONCOGENE (2008)
Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities
Matthias Wolfl et al.
BLOOD (2007)
The switch from latent to productive infection in Epstein-Barr virus-infected B cells is associated with sensitization to NK cell killing
Isabel Y. Pappworth et al.
JOURNAL OF VIROLOGY (2007)
NF-κB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo
SA Keller et al.
BLOOD (2006)
The KSHV oncoprotein vFLIP contains a TRAF-interacting motif and requires TRAF2 and TRAF3 for signalling
I Guasparri et al.
EMBO REPORTS (2006)
SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells
L Dupré et al.
BLOOD (2005)
Post-transplant lymphoproliferative disorders
S Gottschalk et al.
ANNUAL REVIEW OF MEDICINE (2005)
Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo
LL Laichalk et al.
JOURNAL OF VIROLOGY (2005)
Mother-to-child transmission of human herpesvirus-8 in South Africa
M Dedicoat et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Kaposi's sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression:: the role of the NF-κB and JNK/AP1 pathways
JB An et al.
ONCOGENE (2003)
Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells
SM Tugizov et al.
NATURE MEDICINE (2003)
Epstein-Barr nuclear antigen 1-specific CD4+ Th1 cells kill Burkitt's lymphoma cells
C Paludan et al.
JOURNAL OF IMMUNOLOGY (2002)
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections
V Appay et al.
NATURE MEDICINE (2002)
Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy
J Wilkinson et al.
JOURNAL OF VIROLOGY (2002)
Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4+ T-helper 1 responses
A Leen et al.
JOURNAL OF VIROLOGY (2001)
The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell
GJ Babcock et al.
IMMUNITY (2000)
Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population
S Plancoulaine et al.
LANCET (2000)
Human CD4+ T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1
C Münz et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
